Roles of Hepatic Insufficiency, Hepatic Fibrosis, and Inorganic Pyrophosphate in the Progression of Arterial Calcifications
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Individuals with metabolic syndrome (MetS), particularly those with type 2 diabetes (T2D), and/or metabolic dysfunction-associated steatohepatitis or MASH face an elevated risk of major cardiovascular events (MACE). We showed decrease plams level of PPi in patients with liver cirrhosis. We hypothezised that liver transplant should block AC and restore PPi plasma level.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• everyone requiring liver transplantation for the treatment of a chronic liver disease
Locations
Other Locations
France
CHU de Nice
RECRUITING
Nice
Contact Information
Primary
Guillaume FAVRE, PhD
favre.g@chu-nice.fr
+33492039220
Backup
Gullaume Marrane
marrane.g@chu-nice.fr
+33492039220
Time Frame
Start Date: 2025-11-24
Estimated Completion Date: 2029-11-24
Participants
Target number of participants: 95
Treatments
Other: Patients eligible for Hepatit Transplantation
Patients eligible for HT are contacted by a clinical research coordinator, and if they agree, an inclusion visit is arranged. HT takes place according to transplant availability. As soon as the patient is able to return home after HT, a visit is organised, defining the T1 period. A visit is carried out 120 days after HT and the end-of-study visit is scheduled to define the T2 period, which is the same length as the T1 period for each patient.
Related Therapeutic Areas
Sponsors
Leads: Centre Hospitalier Universitaire de Nice